DE69813853D1 - Perforierte mikropartikel und deren verwendung - Google Patents

Perforierte mikropartikel und deren verwendung

Info

Publication number
DE69813853D1
DE69813853D1 DE69813853T DE69813853T DE69813853D1 DE 69813853 D1 DE69813853 D1 DE 69813853D1 DE 69813853 T DE69813853 T DE 69813853T DE 69813853 T DE69813853 T DE 69813853T DE 69813853 D1 DE69813853 D1 DE 69813853D1
Authority
DE
Germany
Prior art keywords
dispersions
patient
suspension medium
microstructures
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69813853T
Other languages
English (en)
Other versions
DE69813853T3 (de
DE69813853T2 (de
Inventor
E Tarara
G Weers
Alexey Kabalnov
G Schutt
A Dellamary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Inhale Therapeutics Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69813853(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inhale Therapeutics Systems Inc filed Critical Inhale Therapeutics Systems Inc
Publication of DE69813853D1 publication Critical patent/DE69813853D1/de
Application granted granted Critical
Publication of DE69813853T2 publication Critical patent/DE69813853T2/de
Publication of DE69813853T3 publication Critical patent/DE69813853T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
DE69813853T 1997-09-29 1998-09-29 Perforierte mikroteilchen und deren verwendung Expired - Lifetime DE69813853T3 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US6033797P 1997-09-29 1997-09-29
US60337 1997-09-29
US10693298A 1998-06-29 1998-06-29
US106932 1998-06-29
US13384898A 1998-08-14 1998-08-14
US133848 1998-08-14
PCT/US1998/020602 WO1999016419A1 (en) 1997-09-29 1998-09-29 Perforated microparticles and methods of use

Publications (3)

Publication Number Publication Date
DE69813853D1 true DE69813853D1 (de) 2003-05-28
DE69813853T2 DE69813853T2 (de) 2004-01-29
DE69813853T3 DE69813853T3 (de) 2011-05-12

Family

ID=27369827

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69813853T Expired - Lifetime DE69813853T3 (de) 1997-09-29 1998-09-29 Perforierte mikroteilchen und deren verwendung
DE69814428T Expired - Lifetime DE69814428T2 (de) 1997-09-29 1998-09-29 In verneblern verwendbare, stabilisierte zubereitungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69814428T Expired - Lifetime DE69814428T2 (de) 1997-09-29 1998-09-29 In verneblern verwendbare, stabilisierte zubereitungen

Country Status (28)

Country Link
EP (4) EP1019021B2 (de)
JP (9) JP5372306B2 (de)
KR (4) KR100575070B1 (de)
CN (1) CN1169520C (de)
AT (3) ATE248583T1 (de)
AU (4) AU756693B2 (de)
BG (1) BG64816B1 (de)
BR (1) BR9812693A (de)
CA (4) CA2304973C (de)
CZ (1) CZ300758B6 (de)
DE (2) DE69813853T3 (de)
DK (2) DK1019022T4 (de)
EA (2) EA003665B1 (de)
EE (1) EE04628B1 (de)
ES (3) ES2195415T3 (de)
HK (1) HK1031680A1 (de)
HR (1) HRP20000175B1 (de)
IL (2) IL135126A0 (de)
IS (1) IS2154B (de)
ME (1) MEP4108A (de)
NO (1) NO340149B1 (de)
NZ (1) NZ503464A (de)
PL (1) PL195212B1 (de)
PT (1) PT1019022E (de)
RS (1) RS50182B (de)
SK (1) SK285068B6 (de)
TR (1) TR200000819T2 (de)
WO (3) WO1999016421A1 (de)

Families Citing this family (233)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
ATE248583T1 (de) * 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
WO2000000215A1 (en) * 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
AU760537B2 (en) * 1998-06-29 2003-05-15 Novartis Ag Particulate delivery systems and methods of use
US6630169B1 (en) 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
DK1180020T4 (da) * 1999-05-27 2009-10-05 Acusphere Inc Poröse lægemiddelmatrixer og fremgangsmåder til fremstilling deraf
EP1185248B1 (de) 1999-06-09 2012-05-02 Robert E. Sievers Überkritische fluidgestützte verneblung und blasen trochnen
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
WO2001013891A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US6761909B1 (en) 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
AU2729101A (en) 1999-12-21 2001-07-03 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
GB0003935D0 (en) * 2000-02-08 2000-04-12 King S College London Formulation for dry powder inhaler
WO2001058697A2 (en) 2000-02-08 2001-08-16 3M Innovative Properties Company Ink fixing materials and methods of fixing ink
AU4905601A (en) 2000-02-08 2001-08-20 3M Innovative Properties Company Improved media for cold image transfer
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
CA2382133C (en) * 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001087277A2 (en) * 2000-05-15 2001-11-22 Vectura Limited Method of manufacturing particles
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US7141236B2 (en) 2000-07-28 2006-11-28 Nektar Therapeutics Methods and compositions for delivering macromolecules to or via the respiratory tract
DE10064219B9 (de) * 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US20030072717A1 (en) 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
GB0106403D0 (en) * 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
EP1390012A4 (de) * 2001-04-26 2009-10-28 Novartis Ag Neue verfahren und zusammensetzungen zur freisetzung von makromolekülen an die oder über die atemwege
US7905230B2 (en) 2001-05-09 2011-03-15 Novartis Ag Metered dose inhaler with lockout
AU2002310054B2 (en) * 2001-05-21 2007-02-01 Injet Digital Aerosols Limited Compositions for protein delivery via the pulmonary route
NZ529417A (en) 2001-05-24 2006-11-30 Alexza Pharmaceuticals Inc Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
WO2002094242A1 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of rizatriptan or zolmitriptan through an inhalation route
EP1397173A1 (de) 2001-06-20 2004-03-17 Nektar Therapeutics Pulveraerosolizationsgerät und verfahren
EP1487417A4 (de) * 2001-09-17 2010-03-17 Glaxo Group Ltd Medikamentöse trockenpulver-formulierungen
AU2002342241B2 (en) 2001-11-01 2007-07-19 Novartis Ag Spray drying methods and compositions thereof
WO2003041693A1 (en) 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
WO2003057188A1 (en) 2001-11-21 2003-07-17 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
AU2002351271A1 (en) 2001-12-21 2003-07-24 Nektar Therapeutics Capsule package with moisture barrier
JPWO2003077891A1 (ja) * 2002-03-18 2005-07-14 アステラス製薬株式会社 吸入用粉末医薬組成物およびその製造方法
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US6941980B2 (en) 2002-06-27 2005-09-13 Nektar Therapeutics Apparatus and method for filling a receptacle with powder
PA8578501A1 (es) 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
CA2500065A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US7516741B2 (en) 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
JP2006511617A (ja) * 2002-12-13 2006-04-06 アダーギット 製薬用多孔質粒子
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7669596B2 (en) 2002-12-31 2010-03-02 Novartis Pharma Ag Aerosolization apparatus with rotating capsule
KR20050095838A (ko) * 2002-12-31 2005-10-04 넥타르 테라퓨틱스 폐 투여용 불용성 활성제를 갖는 약제학적 제형물
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
US8765124B2 (en) 2003-02-28 2014-07-01 Chugai Seiyaku Kabushiki Kaisha Stabilized preparation containing protein
EP1607117A4 (de) 2003-03-27 2007-10-24 Bioactis Ltd Applikator für pulvermedikation in der nasenhöhle
PL1615689T3 (pl) 2003-04-09 2016-06-30 Novartis Ag Urządzenie do aerozolizacji z prowadnicą wyrównującą do przebijania kapsułki
WO2004091705A1 (en) 2003-04-09 2004-10-28 Nektar Therapeutics Aerosolization apparatus with air inlet shield
US8869794B1 (en) 2003-04-09 2014-10-28 Novartis Pharma Ag Aerosolization apparatus with capsule puncturing member
ES2370395T3 (es) 2003-05-21 2011-12-15 Alexza Pharmaceuticals, Inc. Utilización de una capa de combustible sólido, procedimiento para fabricarla y unidad de calefacción correspondiente.
KR101511196B1 (ko) 2003-05-28 2015-04-10 노바르티스 아게 아미노산 및/또는 인지질로 부분 또는 완전 코팅된 수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의 분무 건조법
CA2533887A1 (en) * 2003-09-30 2005-04-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
US7621299B2 (en) 2003-10-03 2009-11-24 Cabot Corporation Method and apparatus for filling a vessel with particulate matter
CA2543296A1 (en) * 2003-10-31 2005-05-12 Point Biomedical Corporation Reconstitutable microsphere compositions useful as ultrasonic contrast agents
US7192919B2 (en) 2004-01-07 2007-03-20 Stelios Tzannis Sustained release compositions for delivery of pharmaceutical proteins
CA2562606A1 (en) * 2004-04-13 2005-10-27 Cambridge Biostability Limited Liquids containing suspended glass particles
ITMI20040795A1 (it) 2004-04-23 2004-07-23 Eratech S R L Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
CN101442989B (zh) 2004-06-21 2013-04-03 诺瓦帝斯公司 包括两性霉素b的组合物
EP1785145A4 (de) 2004-08-10 2008-08-13 Translational Res Ltd Transnasale zusammensetzung mit sofortiger wirkung und hoher resorbierbarkeit
RS51527B2 (sr) 2004-08-13 2018-02-28 Boehringer Ingelheim Int Tabletna formulacija sa produženim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so, postupak za proizvodnju iste i njena primena
CN101849920A (zh) 2004-08-13 2010-10-06 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
BRPI0609700A2 (pt) 2005-03-23 2010-04-20 Elan Pharma Int Ltd formulações de corticosteróide nanoparticulado e antihistamina
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
WO2006124446A2 (en) * 2005-05-12 2006-11-23 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
WO2007030162A2 (en) 2005-05-18 2007-03-15 Nektar Therapeutics Valves, devices, and methods for endobronchial therapy
TW200716174A (en) 2005-05-19 2007-05-01 Centocor Inc Anti-MCP-1 antibodies, compositions, methods and uses
EP1896073B1 (de) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23-antikörper, zusammensetzungen, verfahren und verwendung
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
JP5113328B2 (ja) * 2005-11-07 2013-01-09 田辺三菱製薬株式会社 エマルション並びにそれを用いた目的物質粒子の製造方法及び医薬品
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
RS53685B1 (en) 2005-12-29 2015-04-30 Janssen Biotech Inc. HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS
CA2640165A1 (en) * 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
CN101453982B (zh) 2006-05-30 2011-05-04 精达制药公司 两件式内部通道渗透递送系统流动调节器
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
JP5415769B2 (ja) 2006-12-26 2014-02-12 株式会社新日本科学 経鼻投与用製剤
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
WO2009023803A2 (en) * 2007-08-15 2009-02-19 Abbott Respiratory Llc Modulated release formulation for the delivery of one or more medicaments
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
WO2009120619A2 (en) * 2008-03-24 2009-10-01 Novartis Ag Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
PL220269B1 (pl) 2008-04-21 2015-09-30 Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego
MX2010012452A (es) 2008-05-15 2011-03-15 Novartis Ag Star Suministro pulmonar de una fluoro-quinolona.
US20110166063A1 (en) 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
MX2011004550A (es) 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
AU2009312598A1 (en) * 2008-11-04 2010-05-14 Cipla Limited Pharmaceutical aerosol composition
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2010093627A2 (en) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
EP2221048A1 (de) 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmazeutische Zusammensetzungen zur Inhalation
CA2755809C (en) 2009-03-18 2014-02-18 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
RU2577698C2 (ru) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
KR20100123240A (ko) * 2009-05-15 2010-11-24 포항공과대학교 산학협력단 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
PL2435025T3 (pl) * 2009-05-29 2017-08-31 Pearl Therapeutics, Inc. Dostarczanie substancji czynnych do dróg oddechowych
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
EP3323423B1 (de) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
WO2011069197A1 (en) * 2009-12-08 2011-06-16 The University Of Sydney Inhalable formulations
EP2464346A1 (de) 2010-08-30 2012-06-20 Pulmatrix, Inc. Behandlung zystischer fibrose mit calciumlactat, leukin und natriumchlorid in einem einatembaren trockenpulver
CN105640925B (zh) 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
KR101915241B1 (ko) 2010-09-29 2018-11-06 풀매트릭스 오퍼레이팅 컴퍼니, 인크 흡입용의 1가 금속 양이온 건조 분말
CA2812417C (en) 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
JP2013540827A (ja) * 2010-10-29 2013-11-07 ウエスタン ユニバーシティ オブ ヘルス サイエンシズ 三種混合製剤
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012222074A1 (en) * 2011-02-25 2013-09-12 National Institutes Of Health Chalcone derivatives as Nrf2 activators
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
EA201490991A1 (ru) * 2011-05-17 2014-09-30 Перл Терапьютикс, Инк. Композиции, способы и устройства для респираторной доставки двух или более активных средств
GB201117621D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
EP2601941A1 (de) 2011-12-06 2013-06-12 Ludwig-Maximilians-Universität München Verbindungen auf beta-O/S/N-Fettsäurebasis als Antibakterium- und Antiprotozoenmittel
CA2869849A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
TR201902687T4 (tr) 2013-03-15 2019-03-21 Pearl Therapeutics Inc İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler.
GB201306984D0 (en) * 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
EP3607941A1 (de) 2013-04-30 2020-02-12 Otitopic Inc. Trockenpulverformulierungen und verfahren zur verwendung
KR101543507B1 (ko) * 2013-05-15 2015-08-11 씨제이헬스케어 주식회사 연속 공정의 미립구의 제조 방법 및 이로부터 제조된 미립구
CN110652495A (zh) * 2013-05-23 2020-01-07 Az治疗公司 用于递送色甘酸的方法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
WO2014207213A1 (en) 2013-06-28 2014-12-31 Medizinische Universität Innsbruck Novel inhibitors of protein kinase c epsilon signaling
JP2016534063A (ja) * 2013-10-22 2016-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体ならびに関連するイメージングおよび治療方法
EP3104853B1 (de) 2014-02-10 2019-10-02 Respivant Sciences GmbH Behandlung mit mastzellenstabilisatoren für systemische erkrankungen
SI3104854T1 (sl) 2014-02-10 2020-09-30 Respivant Sciences Gmbh Stabilizatorji mastocitov za zdravljenje pljučnih bolezni
JP6701086B2 (ja) 2014-02-20 2020-05-27 オティトピック インコーポレイテッド 吸入用の乾燥粉末製剤
EP2947460A1 (de) 2014-05-22 2015-11-25 Medizinische Universität Wien Personalisierte Therapie von Entzündungen um Zusammenhang mit Krebs mithilfe von Verfahren zur Bestimmung der Empfänglichkeit auf die Behandlung mit EGFR-Hemmern/-Antagonisten
KR102603897B1 (ko) 2014-07-31 2023-11-20 벡추라 인코포레이티드 흡입용 건조 분말 제형
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation
JP6395216B2 (ja) * 2014-11-13 2018-09-26 国立大学法人大阪大学 液体に含まれる超微細バブルの測定方法及びその測定装置
EP3247332A1 (de) 2015-01-20 2017-11-29 Incarda Therapeutics, Inc. Einheitsaerosoldosen für antikoagulation
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016170102A1 (en) 2015-04-22 2016-10-27 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
EP3302354B1 (de) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Systeme zum einsetzen eines implantats
EP3331522A1 (de) 2015-08-07 2018-06-13 Patara Pharma LLC Verfahren zur behandlung von mastzellbedingten erkrankungen mit mastzellstabilisatoren
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
ES2866175T3 (es) 2015-12-04 2021-10-19 Mexichem Fluor Sa De Cv Composición farmacéutica
DK3386997T3 (da) 2015-12-09 2021-09-20 Univ Wien Med Monomaleimid-funktionaliserede platinforbindelser til cancerterapi
CN109071482A (zh) 2016-01-15 2018-12-21 汉堡大学 携有o-鼠李糖基残基的类黄酮型化合物
JP2019509985A (ja) 2016-02-01 2019-04-11 インカーダ セラピューティクス， インコーポレイテッド 心房細動を含む心不整脈を管理するための吸入薬物療法との電子的監視の組み合せ
MX2018009870A (es) 2016-02-15 2018-11-29 Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh Inhibidores de taf1 para la terapia del cancer.
WO2017172771A2 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
US20190111069A1 (en) 2016-04-15 2019-04-18 Oxford University Innovation Limited Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP2019524721A (ja) 2016-07-15 2019-09-05 ポセイダ セラピューティクス， インコーポレイテッド キメラ抗原受容体および使用方法
EP3484927A1 (de) 2016-07-15 2019-05-22 Poseida Therapeutics, Inc. Für muc1 spezifische chimäre antigenrezeptoren (autos) und verfahren zu deren verwendung
KR20190044647A (ko) 2016-08-31 2019-04-30 더 제너럴 하스피탈 코포레이션 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포
EP3506893A4 (de) 2016-08-31 2020-01-22 Respivant Sciences GmbH Cromolynzusammensetzungen zur behandlung von chronischem husten aufgrund von idiopathischer pulmonaler fibrose
CA3037107C (en) 2016-09-19 2021-05-18 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising salmeterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
IL265349B2 (en) 2016-09-19 2023-03-01 Mexichem Fluor Sa De Cv Pharmaceutical composition
KR20210089273A (ko) 2016-09-19 2021-07-15 멕시켐 플루어 소시에다드 아노니마 데 카피탈 바리아블레 약제학적 조성물
CN116270640A (zh) 2016-09-19 2023-06-23 墨西哥氟石股份公司 药物组合物
CA3037961A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
WO2018067341A1 (en) 2016-10-07 2018-04-12 Patara Pharma, LLC Cromolyn compositions for treatment of pulmonary fibrosis
JP2020511401A (ja) 2016-11-14 2020-04-16 チェム−フォルシュングスツェントルン フュル モレクラーレ メディツィン ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療法のためのｂｒｄ４阻害剤と葉酸代謝拮抗薬との組み合わせ物
KR20190078648A (ko) 2016-11-16 2019-07-04 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 방법
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
EP3621616A4 (de) 2017-05-10 2021-01-13 InCarda Therapeutics, Inc. Einheitsdosen, aerosole, kits und verfahren zur behandlung von herzleiden mittels pulmonaler verabreichung
AU2018273887B2 (en) 2017-05-22 2022-09-08 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof
WO2019017995A1 (en) 2017-07-20 2019-01-24 Aztherapies, Inc. FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN
EP3679145A2 (de) 2017-09-08 2020-07-15 Poseida Therapeutics, Inc. Zusammensetzungen und verfahren für durch chimären ligandenrezeptor (clr) vermittelte bedingte genexpression
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
US20210179591A1 (en) 2017-12-05 2021-06-17 Eth Zurich New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
JP2021507703A (ja) 2017-12-20 2021-02-25 ポセイダ セラピューティクス，インコーポレイティド Ｖｃａｒ組成物とその利用法
KR20200129125A (ko) 2018-03-05 2020-11-17 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
WO2019173636A1 (en) 2018-03-07 2019-09-12 Poseida Therapeutics, Inc. Cartyrin compositions and methods for use
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
WO2019193161A1 (en) 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
WO2019193159A1 (en) 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of hyperhidrosis
US20190345245A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake
JP2021529771A (ja) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
SI3883606T1 (sl) 2018-09-24 2023-10-30 Janssen Biotech, Inc. Varen in učinkovit postopek zdravljenja ulceroznega kolitisa s protitelesom proti IL12/IL23
US11548941B2 (en) 2018-11-20 2023-01-10 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
WO2020127200A1 (en) 2018-12-17 2020-06-25 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
EP3897722A4 (de) 2018-12-18 2022-09-14 Janssen Biotech, Inc. Sichere und wirksame methode zur behandlung von lupus mit anti-il12/il23-antikörper
BR112021013156A2 (pt) 2019-01-03 2021-09-14 Aqua Yield Operations LLC Dendrímeros de pamam para entrega de fertilizante
JP2022525145A (ja) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体組成物を生成するための製造方法
EA202192459A1 (ru) 2019-03-18 2021-11-25 Янссен Байотек, Инк. Способ лечения псориаза антителом к il12/il23 у субъектов детского возраста
US11932585B2 (en) * 2019-04-12 2024-03-19 Aqua Yield Operations LLC Blended nanoparticle fertilizer delivery
CN110051868A (zh) * 2019-04-15 2019-07-26 宝盈联华(厦门)生物科技有限公司 一种带有硅碳岩、礌石粉的橱柜灭菌器
JP7404671B2 (ja) * 2019-06-25 2023-12-26 株式会社リコー 多孔質微粒子及びその製造方法、並びに医薬組成物
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
CA3153456A1 (en) 2019-10-02 2021-04-08 Stefanie Fluckiger-Mangual Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
WO2021064141A1 (en) 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
WO2021074418A1 (en) 2019-10-16 2021-04-22 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
AU2020366135A1 (en) 2019-10-16 2022-06-02 Proxygen Gmbh Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
CN115996747A (zh) 2020-04-14 2023-04-21 波赛达治疗公司 用于治疗癌症的组合物和方法
EP4138884A1 (de) 2020-04-20 2023-03-01 Sorrento Therapeutics, Inc. Pulmonale verabreichung von ace2-polypeptiden
WO2021214587A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating viral infections
WO2021214588A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating coronavirus infections
EP4171562A1 (de) 2020-06-25 2023-05-03 Tolremo Therapeutics AG Heterocyclische derivate, pharmazeutische zusammensetzungen und deren verwendung bei der behandlung, linderung oder prävention von fibrotischen erkrankungen
EP3939578A1 (de) 2020-07-13 2022-01-19 Novaremed Ltd. Verbindungen zur behandlung oder vorbeugung einer infektion, die aus einer coronavirus- und/oder einer coronavirusinduzierten erkrankung resultiert
CN111700883B (zh) * 2020-07-23 2021-04-06 深圳大佛药业股份有限公司 一种硫酸沙丁胺醇缓释型吸入制剂及其生产工艺
EP4208154A1 (de) 2020-09-04 2023-07-12 Mexichem Fluor S.A. de C.V. Pharmazeutische zusammensetzung
EP3964497A1 (de) 2020-09-04 2022-03-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Substituierte vicinale diaminverbindungen und deren verwendung zur behandlung, linderung oder vorbeugung von schmerzen
WO2022079290A2 (en) 2020-10-16 2022-04-21 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Cullin ring ubiquitin ligase compounds and uses thereof
CN112495316B (zh) * 2020-10-20 2021-11-19 大连理工大学 一种基于亚稳态乳液制备微纳米凝胶微球的方法
CN116546980A (zh) * 2020-12-11 2023-08-04 江苏恒瑞医药股份有限公司 用于肺部递送的药物组合物
AU2022232007A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
CA3212729A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
WO2022189662A1 (en) 2021-03-12 2022-09-15 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt
AR125312A1 (es) 2021-04-07 2023-07-05 Tolremo Therapeutics Ag Derivados heterocíclicos, composiciones farmacéuticas y su uso en el tratamiento o la mejora del cáncer
US20230038355A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023203174A1 (en) 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1410588A (en) † 1971-08-10 1975-10-22 Fisons Ltd Composition
JPS5134879A (en) * 1974-09-19 1976-03-24 Eisai Co Ltd Bishochukuryushinoseizoho
US4147766A (en) † 1976-06-09 1979-04-03 Armour Pharmaceutical Company Macrospherical particles of anti-perspirants
DE3268533D1 (en) † 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
JP2867404B2 (ja) * 1983-11-14 1999-03-08 ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション ドラッグデリバリーのための多孔性ミクロスフェアおよびその製造法
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
GB8502892D0 (en) * 1985-02-05 1985-03-06 Sterwin Ag Aerosol composition
WO1986006959A1 (en) * 1985-05-22 1986-12-04 Liposome Technology, Inc. Liposome inhalation method and system
US4950477A (en) † 1988-08-23 1990-08-21 Memorial Hospital For Cancer And Allied Dieseas Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
ATE99546T1 (de) * 1989-05-01 1994-01-15 Alkermes Inc Verfahren zur herstellung von kleinen partikeln von biologisch aktiven molekuelen.
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
JPH05507090A (ja) * 1990-05-08 1993-10-14 リポサーム　テクノロジー　インコーポレイテッド 直接噴霧乾燥された薬剤／脂質粉末組成物
US5126123A (en) † 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5230884A (en) † 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5304125A (en) † 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
DK0495187T3 (da) * 1991-01-15 1997-08-11 Hemosphere Inc Protein-nanomatricer og fremstillingsmetode.
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5182097A (en) † 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
WO1992016192A1 (en) † 1991-03-15 1992-10-01 Amgen Inc. Pulmonary administration of granulocyte colony stimulating factor
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
JPH05500229A (ja) * 1991-04-12 1993-01-21 東レ株式会社 固体ポリペプチド微粒子のエアロゾル製剤とその製造方法
DK0656207T4 (da) * 1991-06-10 2009-11-30 Schering Corp Aerosolformuleringer uden chlorfluorcarbonforbindelser
ES2216800T3 (es) * 1991-12-18 2004-11-01 Minnesota Mining And Manufacturing Company Formulaciones de aerosol en suspension.
US5376359A (en) † 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5354934A (en) † 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
US5798091A (en) † 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
DE69434119T3 (de) * 1993-07-30 2011-05-05 Imcor Pharmaceutical Co., San Diego Stabilisierte mikrogasbläschen-zusammensetzungen für echographie
EP0655237A1 (de) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
CA2199954A1 (en) * 1994-09-29 1996-04-04 Andrew Derek Sutton Spray-dried microparticles as therapeutic vehicles
GB9423419D0 (en) * 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
PL320856A1 (en) * 1994-12-22 1997-11-10 Astra Ab Aerosol drug preparations
KR19980703876A (ko) * 1995-04-14 1998-12-05 스티븐 엘. 허스트 분산성이 개선된 분말화된 약학적 조성물
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
DE69632401T2 (de) † 1995-06-07 2005-05-19 Imarx Pharmaceutical Corp., Tucson Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung
US6041777A (en) * 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
EP0954282B1 (de) † 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
ATE248583T1 (de) * 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen

Also Published As

Publication number Publication date
KR20010030787A (ko) 2001-04-16
CA2304975A1 (en) 1999-04-08
IS2154B (is) 2006-10-13
ES2195415T3 (es) 2003-12-01
RS50182B (sr) 2009-05-06
DK1019021T3 (da) 2003-11-10
AU1185799A (en) 1999-04-23
DE69814428T2 (de) 2004-05-13
ATE248583T1 (de) 2003-09-15
PL339732A1 (en) 2001-01-02
SK285068B6 (sk) 2006-05-04
CA2304820A1 (en) 1999-04-08
JP2003525841A (ja) 2003-09-02
CN1272058A (zh) 2000-11-01
EE200000194A (et) 2001-04-16
EP1019023B1 (de) 2003-05-07
DK1019021T4 (da) 2013-01-07
JP6100114B2 (ja) 2017-03-22
JP2014169335A (ja) 2014-09-18
YU18300A (sh) 2003-02-28
IS5415A (is) 2000-03-24
DE69814428D1 (de) 2003-06-12
EE04628B1 (et) 2006-06-15
IL135126A (en) 2006-04-10
HRP20000175A2 (en) 2001-06-30
JP2003525842A (ja) 2003-09-02
JP2011116788A (ja) 2011-06-16
EA200000375A1 (ru) 2000-12-25
SK4492000A3 (en) 2000-09-12
KR20010030801A (ko) 2001-04-16
KR100599634B1 (ko) 2006-07-12
JP2013199497A (ja) 2013-10-03
KR20010030788A (ko) 2001-04-16
WO1999016419A9 (en) 1999-08-19
WO1999016422A1 (en) 1999-04-08
ES2195408T5 (es) 2010-11-25
JP2010047615A (ja) 2010-03-04
CN1169520C (zh) 2004-10-06
EP1019021A1 (de) 2000-07-19
AU750567B2 (en) 2002-07-25
CA2304973C (en) 2009-11-17
DK1019022T3 (da) 2003-07-28
CZ20001115A3 (cs) 2000-09-13
AU757337B2 (en) 2003-02-20
EP1019021B1 (de) 2003-09-03
EA200200036A1 (ru) 2002-04-25
CA2304973A1 (en) 1999-04-08
MEP4108A (xx) 2010-02-10
AU756693B2 (en) 2003-01-23
JP5739197B2 (ja) 2015-06-24
NZ503464A (en) 2002-05-31
NO20001618D0 (no) 2000-03-28
KR100572171B1 (ko) 2006-04-19
EP1019021B2 (de) 2012-12-26
AU757337C (en) 2005-11-03
CZ300758B6 (cs) 2009-08-05
NO340149B1 (no) 2017-03-13
KR20010030810A (ko) 2001-04-16
AU757153B2 (en) 2003-02-06
CA2304975C (en) 2009-06-16
DK1019022T4 (da) 2010-11-08
ES2205560T5 (es) 2013-04-16
ATE238035T1 (de) 2003-05-15
HRP20000175B1 (en) 2004-06-30
BG104253A (en) 2000-11-30
AU9677298A (en) 1999-04-23
BG64816B1 (bg) 2006-05-31
WO1999016419A1 (en) 1999-04-08
TR200000819T2 (tr) 2001-06-21
EA002562B1 (ru) 2002-06-27
KR100589926B1 (ko) 2006-06-15
WO1999016421A1 (en) 1999-04-08
IL135126A0 (en) 2001-05-20
DE69813853T3 (de) 2011-05-12
CA2304820C (en) 2009-06-23
KR100575070B1 (ko) 2006-05-03
JP6078498B2 (ja) 2017-02-08
BR9812693A (pt) 2000-08-22
JP2013216688A (ja) 2013-10-24
CA2304819C (en) 2008-04-08
EP1019020A1 (de) 2000-07-19
JP5372306B2 (ja) 2013-12-18
EP1019023A1 (de) 2000-07-19
EP1019022B1 (de) 2003-04-23
DE69813853T2 (de) 2004-01-29
EP1019022A1 (de) 2000-07-19
PT1019022E (pt) 2003-08-29
EA003665B1 (ru) 2003-08-28
JP2001517692A (ja) 2001-10-09
PL195212B1 (pl) 2007-08-31
JP2001517691A (ja) 2001-10-09
HK1031680A1 (en) 2001-06-22
ES2195408T3 (es) 2003-12-01
ES2205560T3 (es) 2004-05-01
AU9677098A (en) 1999-04-23
NO20001618L (no) 2000-05-19
CA2304819A1 (en) 1999-04-08
AU1064499A (en) 1999-04-23
ATE239447T1 (de) 2003-05-15
JP4526702B2 (ja) 2010-08-18
EP1019022B2 (de) 2010-07-28

Similar Documents

Publication Publication Date Title
DE69813853D1 (de) Perforierte mikropartikel und deren verwendung
PT904056E (pt) Processo e dispositivo para inalacao de medicamentos particulados
GR3026516T3 (en) Inhalation powders and method of manufacturing them.
SE9701956D0 (sv) New composition of matter
ES2177544T3 (es) Polvo ultrafinno para inhalar y metodo para su preparacion.
DE59209660D1 (de) Pulverinhalator mit pulverträger aus regelmässigen mikrostrukturen
ATE265204T1 (de) Micropartikeln zur verwendung in nadellosen injektion
KR930701992A (ko) 환자의 폐에 잔존하는 점액 분비물의 제거 방법
FI20002216A0 (fi) Yhdistelmäpartikkelit astman hoitoon
DE60008425D1 (de) Medikamentenabgabevorrichtung mit einer feuchtigkeitsbeständigen beschichtung
ATE271852T1 (de) Verbesserte inhalationspräparate
Molev et al. Efficacy of treating new cases of destructive tuberculosis of the lungs in alcoholism.
SE9402383D0 (sv) Förfarande och anordning för att införa ett ämne till ett slutet utrymme

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: NEKTAR THERAPEUTICS (N.D.GES.D. STAATES DELAWARE),

8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS AG, BASEL, CH